TITLE

suzhou PHARMA SERVICES

PUB. DATE
December 2012
SOURCE
Contract Pharma;2013 Corporate Capabilities & Contract Services Directory, p212
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on Lyndhurst, New Jersey-based pharmaceutical company Suzhou Pharma Services. It mentions that Suzhou is a contract and manufacturing organization working with U.S. Food and Drug Administration (FDA) and Chinese government-approved drugs. It adds that the company provides cost-efficient development and efficient way of manufacturing pharmaceutical products as well as supporting Phase IV clinical trials.
ACCESSION #
85097840

 

Related Articles

  • Taking the 505(b)(2) Route. Phelps, Kenneth V. // Drug Discovery & Development;Jul/Aug2012, Vol. 15 Issue 7, p24 

    The article focuses on essentials of the Section 505(b)(2) regulatory pathway to the U.S. Food and Drug Administration (FDA) drug approval. It claims that one huge advantage of drugs approved under the 505(b)(2) is the reliance of drug manufacturers from existing reference drugs which allow much...

  • Clinic Roundup.  // BioWorld Today;8/15/2012, Vol. 23 Issue 158, p2 

    This section offers news briefs on clinical trials in the biopharmaceutical industry. A Phase II study of Trichuris suis ova in patients with Crohn's disease was initiated by Coronado Biosciences Inc. Proteonomix Inc. has received a U.S. Food and Drug Administration approval to start its UMK-121...

  • Product Preview.  // Urology Times;8/15/2006, Vol. 34 Issue 10, p35 

    The article presents news briefs concerning pharmaceutical product developments. The immunotherapy agent TroVax for advanced renal cell carcinoma developed by Oxford BioMedica has received a special protocol assessment agreement for a phase III trial from the U.S. Food and Drug Administration....

  • Change is Assured. Studt, Tim // Drug Discovery & Development;Jul/Aug2013, Vol. 16 Issue 4, p4 

    The author reflects on the changes in the biopharmaceutical industry in the U.S. He emphasizes the increase in the number of new drugs approved by the U.S. Food and Drug Administration (FDA) from 30 in 2011 to 39 in 2012. He highlights the trends in the merger and acquisition (M&A) strategies of...

  • Electronic Data in Clinical Investigations. Heisey, Colleen // Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p18 

    The article reports on the revision of the U.S. Food and Drug Administration's (FDA) draft guidance document addressing comments associated to the pharmaceutical industry. FDA revises the source data from clinical investigations incorporated with an electronic case report form's (eCRF)...

  • Treating Alzheimer's Early. O'Donohoe, Paul // Applied Clinical Trials;Mar2013, Vol. 22 Issue 3, p12 

    The article offers information on a plan released by the U.S. Food and Drug Administration (FDA) for pre-dementia Alzheimer's trials. It informs about electronic clinical outcome assessments (eCOA) and clinician reported outcomes (ClinROs) which can provide life science companies an easier way...

  • Pediatrics Come up Short In Postmarket Requirements. Serebrov, Mari // BioWorld Today;3/6/2012, Vol. 23 Issue 44, p1 

    The article discusses the U.S. Food and Drug Administration's (FDA) annual report on how drugmakers are doing in meeting their postmarket requirements (PMRs) and commitments (PMCs). It is noted in the report that almost 22 percent of the 55 open PMRs in 2011 were behind schedule. A delay in the...

  • Clinical operations generation next... The age of technology and outsourcing. Temkar, Priya // Perspectives in Clinical Research;Oct-Dec2015, Vol. 6 Issue 4, p175 

    Huge cost pressures and the need to drive faster approvals has driven a technology transformation in the clinical trial (CT) industry. The CT industry is thus leveraging mobile data, cloud computing, social media, robotic automation, and electronic source to drive efficiencies in a big way....

  • Antidepressants: FDA research may lead to adult warnings.  // PharmaWatch: CNS;November 2004, Vol. 3 Issue 11, p11 

    Reports on the U.S. Food and Drug Administration's examination of the potential link between antidepressants and increased suicidal tendencies in adults. Proposals for more "black box" labels for antidepressants; Consideration of revenues of pharmaceutical firms; Clinical trials required for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics